Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | BLVRB | P30043 | 1/20 | 0.47 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019133 | 1.00 | XDH (0.53) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL2641631 | 0.86 | XDH (0.41) | XDHSLC22A12 | |
| SCHEMBL31573 | 0.85 | XDH (0.69) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL13182575 | 0.83 | XDH (0.53) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL12455378 | 0.83 | MRGPRX4 (0.48) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL28291444 | 0.83 | ALDH1A1 (0.45) | XDHSLC22A12 | |
| SCHEMBL6052309 | 0.82 | ALDH1A1 (0.63) | XDHSLC22A12 | |
| SCHEMBL31571 | 0.82 | AAK1 (0.57) | XDHSLC22A12 | |
| SCHEMBL2636175 | 0.82 | ALDH1A1 (0.42) | XDHSLC22A12 | |
| SCHEMBL3746804 | 0.82 | AR (0.50) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620829-B | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-113620829-A | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2021-11-09 | — | — | CN | claimed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| CN-113620829-B | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-113620829-B | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-113620832-A | Preparation method of febuxostat intermediate | 鲁南制药集团股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620832-A | Preparation method of febuxostat intermediate | 鲁南制药集团股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620829-A | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620829-A | Febuxostat intermediate compound | 鲁南制药集团股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-103175905-B | Method for determining impurities in febuxostat and its preparation through high performance liquid chromatography | BEIJING BENCAO TIANYUAN PHARMACEUTICAL RES INST | 2015-07-15 | — | — | CN | disclosed |
| US-20140228417-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | MAPI PHARMA LTD. (IL) | 2014-08-14 | — | — | US | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011101867-A2 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101867-A2 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| EP-1471065-B1 | NOVEL 1,2,4-TRIAZOLE COMPOUND | FUJI YAKUHIN CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7074816-B2 | 1 2 4-triazole compound | FUJI YAKUHIN CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20050004175-A1 | Novel 1 2 4-triazole compound | FUJI YAKUHIN CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1471065-A1 | NOVEL 1,2,4-TRIAZOLE COMPOUND | Fuji Yakuhin Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004175-A1 | Novel 1 2 4-triazole compound | XDH, PNPO, NOX1 | XDH 1/4885SLC22A12 1309/4885ABCC4 416/4885 |
| US-20140228417-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | XDH, NLRP3, PNPO | XDH 1/4885SLC22A12 1390/4885ABCC4 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.